Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

542 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis.
Camerini A, Banna GL, Cinieri S, Pezzuto A, Mencoboni M, Rosetti F, Figueiredo A, Rizzo P, Ricci A, Langenhoven L, Santo A, Addeo A, Amoroso D, Barata F. Camerini A, et al. Among authors: santo a. Clin Transl Oncol. 2019 Jun;21(6):790-795. doi: 10.1007/s12094-018-1989-y. Epub 2018 Nov 17. Clin Transl Oncol. 2019. PMID: 30448956
Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
Tummarello D, Graziano F, Isidori P, Santo A, Cetto G, Fedeli A, Rossi G, Cellerino R. Tummarello D, et al. Among authors: santo a. Cancer. 1996 Jun 1;77(11):2251-7. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2251::AID-CNCR11>3.0.CO;2-W. Cancer. 1996. PMID: 8635092 Clinical Trial.
A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D, Mari D, Graziano F, Isidori P, Cetto G, Pasini F, Santo A, Cellerino R. Tummarello D, et al. Among authors: santo a. Cancer. 1997 Dec 15;80(12):2222-9. Cancer. 1997. PMID: 9404698 Clinical Trial.
Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial.
Ridolfi L, Bertetto O, Santo A, Naglieri E, Lopez M, Recchia F, Lissoni P, Galliano M, Testore F, Porta C, Maglie M, Dall'agata M, Fumagalli L, Ridolfi R. Ridolfi L, et al. Among authors: santo a. Int J Oncol. 2011 Oct;39(4):1011-7. doi: 10.3892/ijo.2011.1099. Epub 2011 Jun 24. Int J Oncol. 2011. PMID: 21720704 Clinical Trial.
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF. Ardizzoni A, et al. Among authors: santo a. J Clin Oncol. 2012 Dec 20;30(36):4501-7. doi: 10.1200/JCO.2012.43.6758. Epub 2012 Oct 29. J Clin Oncol. 2012. PMID: 23109689 Clinical Trial.
542 results